CG
PHAT icon

Cutler Group’s Phathom Pharmaceuticals PHAT Stock Holding History

Cutler Group’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-50
Closed -$431 – 4162
2023
Q3 		$0 Sell
50
-1,150
-96% -$15.8K ﹤0.01% 4199
2023
Q2 		$17K Buy
1,200
+100
+9% +$1.15K ﹤0.01% 1946
2023
Q1 		$7K Buy
1,100
+700
+175% +$6.15K ﹤0.01% 2558
2022
Q4 		$4K Hold
400
– – ﹤0.01% 3342
2022
Q3 		$4K Sell
400
-200
-33% -$1.91K ﹤0.01% 3826
2022
Q2 		$5K Hold
600
– – ﹤0.01% 3742
2022
Q1 		$8K Hold
600
– – ﹤0.01% 3798
2021
Q4 		$11K Hold
600
– – ﹤0.01% 3630
2021
Q3 		$19K Sell
600
-100
-14% -$3.32K ﹤0.01% 3391
2021
Q2 		$23K Hold
700
– – ﹤0.01% 3190
2021
Q1 		$26K Buy
+700
New +$29.3K ﹤0.01% 2986
2020
Q2 		– Sell
-400
Closed -$10K – 4750
2020
Q1 		$10K Buy
+400
New +$13.4K ﹤0.01% 2723

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Cutler Group's PHAT Position: Q4 2023 in Review

Cutler Group sold out of Phathom Pharmaceuticals (PHAT) in Q4 2023, closing a stake of 50 shares — an estimated $431 sold.

Cutler Group first reported a position in PHAT in Q1 2020 and held it in 12 quarters. The position peaked at $26K in Q1 2021. 117 funds tracked by Wall St. Rank hold PHAT as of Q4 2023.

  • Cutler Group reported no remaining Phathom Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Cutler Group sold 50 Phathom Pharmaceuticals shares in Q4 2023, an estimated $431.
  • Cutler Group first reported a position in Phathom Pharmaceuticals in Q1 2020 and held it in 12 quarters.
  • Cutler Group's Phathom Pharmaceuticals position peaked at $26K in Q1 2021.
  • 117 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q4 2023.

Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.